The field of extracellular vesicle (EV) research has developed rapidly over the last decade
from the study of fundamental biology to a subject of significant clinical relevance. The …

Defective genes account for∼ 80% of the total of more than 7,000 diseases known to date.
Gene therapy brings the promise of a one-time treatment option that will fix the errors in …

Cancer is a leading public health problem worldwide. Its treatment remains a daunting
challenge, although significant progress has been made in existing treatments in recent …

The term 'extracellular vesicles' refers to a heterogeneous population of vesicular bodies of
cellular origin that derive either from the endosomal compartment (exosomes) or as a result …

Extracellular vesicles (EVs) are nanometer-sized, lipid membrane–enclosed vesicles
secreted by most, if not all, cells and contain lipids, proteins, and various nucleic acid …

Extracellular vesicles (EVs) are diverse, nanoscale membrane vesicles actively released by
cells. Similar-sized vesicles can be further classified (eg, exosomes, microvesicles) based …

Gene vectors are nucleic acids that carry genetic materials or gene editing devices into cells
to exert the sustained production of therapeutic proteins or to correct erroneous genes of the …

Stroke is a leading cause of disability worldwide, and brain injuries devastate patients and
their families, but currently no drugs on the market promote neurological recovery. Limited …

In recent years, adeno-associated virus (AAV) has become the most important vector for
central nervous system (CNS) gene therapy. AAV has already shown promising results in …

Progress in deciphering the genetic architecture of human sensorineural hearing
impairment (SNHI) or loss, and multidisciplinary studies of mouse models, have led to the …